A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers

PURPOSE: To compare pharmacokinetics, safety, tolerability, and immunogenicity between SB8, a bevacizumab biosimilar, and the European Union (EU) and United States (US) reference products (bevacizumab-EU, bevacizumab-US). METHODS: In this randomized, double-blind, parallel-group, and single-dose stu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Chemother Pharmacol
Hlavní autoři: Shin, Donghoon, Lee, Yoon Jung, Choi, Jihye, Lee, Dahyoung, Park, Minjeong, Petkova, Magdalena
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2020
Témata:
Clinical Trial Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515939/
https://ncbi.nlm.nih.gov/pubmed/32949267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04144-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky